NCT06654050 2026-03-17
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
Clinical Trials
981 trialsNCT06297629 2026-02-24
A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT06829199 2026-02-19
MK-5890-003
Merck Sharp & Dohme LLC
Phase 2 Withdrawn
NCT06868238 2026-02-18
Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS)
University of Florida
Phase 2 Withdrawn
NCT05487859 2026-02-17
Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)
University of Alabama at Birmingham
Phase 2 Withdrawn
NCT06501989 2026-02-11
Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer
Inova Health Care Services
Phase 2 Withdrawn
NCT07323576 2026-02-09
INAVO-CRC
Hoffmann-La Roche
Phase 2 Withdrawn
NCT04285268 2026-01-30
Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Rutgers, The State University of New Jersey
Phase 2 Withdrawn
NCT06068881 2026-01-30
Mandolin
Ipsen
Phase 2 Withdrawn
NCT06012929 2026-01-26
A Study of ONC201 for Refractory Meningioma
University of Nebraska
Phase 2 Withdrawn
NCT05846724 2026-01-22
PULSAR
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Phase 2 Withdrawn
NCT06967987 2026-01-21
BEMAFLOT
Institut Cancerologie de l'Ouest
Phase 2 Withdrawn
NCT06646016 2025-12-26
EPIC
Therakos LLC
Phase 2 Withdrawn
NCT07283848 2025-12-26
Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma
Massachusetts General Hospital
Phase 2 Withdrawn
NCT06613516 2025-12-24
CaptAin
Imperial College London
Phase 2 Withdrawn
NCT06804850 2025-11-19
Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC
West China Hospital
Phase 2 Withdrawn
NCT06994299 2025-11-18
PRISM
Weill Medical College of Cornell University
Phase 2 Withdrawn
NCT07026916 2025-11-17
A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer
Genfleet Therapeutics (Shanghai) Inc.
Phase 2 Withdrawn
NCT04910425 2025-10-21
PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer
Northwestern University
Phase 2 Withdrawn
NCT05564416 2025-10-21
Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT06557278 2025-10-21
COMUNITY
Mirror Biologics, Inc.
Phase 2 Withdrawn
NCT06392841 2025-10-20
HARMONY
Hoosier Cancer Research Network
Phase 2 Withdrawn
NCT04419181 2025-10-14
Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer
University of Rochester
Phase 2 Withdrawn
NCT06730100 2025-10-06
CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT05046782 2025-09-30
Abbreviated Biparametric MRI (RSI + T2WI) for Prostate Cancer Detection: Correlation With Histopathology
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT06527690 2025-09-29
REPRESENTATION
Latin American Cooperative Oncology Group
Phase 2 Withdrawn
NCT06528210 2025-09-23
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Withdrawn
NCT04784221 2025-09-17
NANOPRO
Centre Francois Baclesse
Phase 2 Withdrawn
NCT05472623 2025-09-15
Neo-Kan
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Withdrawn
NCT06410534 2025-09-11
A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT06690281 2025-09-11
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT00210171 2025-09-10
BIB 01
Institut Bergonié
Phase 2 Withdrawn
NCT06084689 2025-09-02
EMPIRE
Institut Bergonié
Phase 2 Withdrawn
NCT06555263 2025-08-22
Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer
Sutro Biopharma, Inc.
Phase 2 Withdrawn
NCT04756765 2025-08-17
Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer
Stanford University
Phase 2 Withdrawn
NCT06762808 2025-08-15
Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT04118036 2025-08-11
Abemaciclib + Pembrolizumab In Glioblastoma
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT04571710 2025-07-24
A Trial of SHR1258 in Patients With Biliary Tract Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Withdrawn
NCT06498518 2025-07-11
PRIMUS006
University of Glasgow
Phase 2 Withdrawn
NCT06508827 2025-07-09
Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma
Indiana University
Phase 2 Withdrawn
NCT06940804 2025-07-02
AVENTURINE
BioNTech SE
Phase 2 Withdrawn
NCT05620914 2025-06-15
PARAMETer
Duke University
Phase 2 Withdrawn
NCT06839872 2025-06-05
BOSS
AstraZeneca
Phase 2 Withdrawn
NCT02077621 2025-06-04
Study of PG2 Injection for Improving Fatigue in Patients After Palliative Abdominal Surgery for Cancer
PhytoHealth Corporation
Phase 2 Withdrawn
NCT05840770 2025-05-26
Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer
City of Hope Medical Center
Phase 2 Withdrawn
NCT06361758 2025-05-23
Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC
Shanghai Zhongshan Hospital
Phase 2 Withdrawn
NCT04685915 2025-05-22
Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT06895577 2025-05-21
Neoadjuvant Chemoradiotherapy Plus Sintilimab for MSS, Locally Advanced Rectal Cancer-
Sun Yat-sen University
Phase 2 Withdrawn
NCT01125449 2025-05-18
Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease
Situs Cancer Research Center
Phase 2 Withdrawn
NCT03879811 2025-05-15
Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Withdrawn